TY - JOUR
T1 - Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer
AU - Saito, Toshiaki
AU - Tabata, Tsutomu
AU - Ikushima, Hitoshi
AU - Yanai, Hiroyuki
AU - Tashiro, Hironori
AU - Niikura, Hitoshi
AU - Minaguchi, Takeo
AU - Muramatsu, Toshinari
AU - Baba, Tsukasa
AU - Yamagami, Wataru
AU - Ariyoshi, Kazuya
AU - Ushijima, Kimio
AU - Mikami, Mikio
AU - Nagase, Satoru
AU - Kaneuchi, Masanori
AU - Yaegashi, Nobuo
AU - Udagawa, Yasuhiro
AU - Katabuchi, Hidetaka
N1 - Funding Information:
Funding Preparation of these guidelines was funded by the JSGO. Some support was received from the General Research Project to Promote Anti-cancer Measures (FY2014), a research subsidy program of Japan’s Ministry of Health, Labour and Welfare (MHLW), under the rubric “research to promote dissemination of guidelines on the treatment of cancer and the results of said dissemination, and research regarding the desired state of said guideline project” (research representative: Koichi Hirata). The expense incurred had no influence on the contents of these guidelines.
Publisher Copyright:
© 2017, The Author(s).
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background: Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines for the treatment of vulvar cancer and vaginal cancer was published in 2015 in Japanese. Objective: The JSGO committee decided to publish the English version of the JSGO guidelines worldwide, and hope it will be a useful guide to physicians in a similar situation as in Japan. Methods: The guideline was created according to the basic principles in creating the guidelines of JSGO. Results: The guidelines consist of five chapters and five algorithms. Prior to the first chapter, basic items are described including staging classification and history, classification of histology, and definition of the methods of surgery, radiation, and chemotherapy to give the reader a better understanding of the contents of the guidelines for these rare tumors. The first chapter gives an overview of the guidelines, including the basic policy of the guidelines. The second chapter discusses vulvar cancer, the third chapter discusses vaginal cancer, and the fourth chapter discusses vulvar Paget’s disease and malignant melanoma. Each chapter includes clinical questions, recommendations, backgrounds, objectives, explanations, and references. The fifth chapter provides supplemental data for the drugs that are mentioned in the explanation of clinical questions. Conclusion: Overall, the objective of these guidelines is to clearly delineate the standard of care for vulvar and vaginal cancer with the goal of ensuring a high standard of care for all women diagnosed with these rare diseases.
AB - Background: Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines for the treatment of vulvar cancer and vaginal cancer was published in 2015 in Japanese. Objective: The JSGO committee decided to publish the English version of the JSGO guidelines worldwide, and hope it will be a useful guide to physicians in a similar situation as in Japan. Methods: The guideline was created according to the basic principles in creating the guidelines of JSGO. Results: The guidelines consist of five chapters and five algorithms. Prior to the first chapter, basic items are described including staging classification and history, classification of histology, and definition of the methods of surgery, radiation, and chemotherapy to give the reader a better understanding of the contents of the guidelines for these rare tumors. The first chapter gives an overview of the guidelines, including the basic policy of the guidelines. The second chapter discusses vulvar cancer, the third chapter discusses vaginal cancer, and the fourth chapter discusses vulvar Paget’s disease and malignant melanoma. Each chapter includes clinical questions, recommendations, backgrounds, objectives, explanations, and references. The fifth chapter provides supplemental data for the drugs that are mentioned in the explanation of clinical questions. Conclusion: Overall, the objective of these guidelines is to clearly delineate the standard of care for vulvar and vaginal cancer with the goal of ensuring a high standard of care for all women diagnosed with these rare diseases.
KW - Clinical practice guidelines
KW - Malignant melanoma of the vulva and vagina
KW - Treatment
KW - Vaginal cancer
KW - Vulvar Paget’s disease
KW - Vulvar cancer
UR - http://www.scopus.com/inward/record.url?scp=85034589264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034589264&partnerID=8YFLogxK
U2 - 10.1007/s10147-017-1193-z
DO - 10.1007/s10147-017-1193-z
M3 - Article
C2 - 29159773
AN - SCOPUS:85034589264
SN - 1341-9625
VL - 23
SP - 201
EP - 234
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 2
ER -